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11-Hydroxysteroid Dehydrogenase Type 2 Deficiency
Accelerates Atherogenesis and Causes Proinflammatory
Changes in the Endothelium inApoe/Mice
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David G. Brownstein, David J. Webb, John J. Mullins, Karen Chapman,
Jonathan R. Seckl, and Yuri V. Kotelevtsev
Centre for Cardiovascular Science (G.A.D., D.M., P.W.F.H., D.G.B., D.J.W., J.J.M., K.C., J.R.S.), The
Queen’s Medical Research Institute, College of Medicine and Veterinary Medicine, University of
Edinburgh, Edinburgh EH16 4TJ, United Kingdom; and Puschino State University (Y.V.K.), 142292
Russia, Puschino, Moscow Region
Mineralocorticoid receptor (MR) activation is proinflammatory and proatherogenic. Antagonism of
MR improves survival in humans with congestive heart failure caused by atherosclerotic disease. In
animal models, activation of MR exacerbates atherosclerosis. The enzyme 11-hydroxysteroid dehy-
drogenase type 2 (11-HSD2) prevents inappropriate activation of theMR by inactivating glucocorti-
coids inmineralocorticoid-target tissues. Todeterminewhetherglucocorticoid-mediatedactivationof
MRincreasesatheromatousplaqueformation,wegeneratedApoe//11-HSD2/double-knockout
(E/b2) mice. On chow diet, E/b2 mice developed atherosclerotic lesions by 3 months of age, whereas
Apolipoprotein E (Apoe/) mice remained lesion free. Brachiocephalic plaques in 3-month-old E/b2
mice showed increased macrophage and lipid content and reduced collagen content compared with
similar sized brachiocephalic plaques in 6-month-old Apoe/mice. Crucially, treatment of E/b2 mice
with eplerenone, anMRantagonist, reduced plaque development andmacrophage infiltrationwhile
increasing collagen and smooth muscle cell content without any effect on systolic blood pressure. In
contrast, reduction of systolic blood pressure in E/b2mice using the epithelial sodium channel blocker
amilorideproduceda less-profoundatheroprotective effect. Vascular cell adhesionmolecule 1expres-
sion was increased in the endothelium of E/b2 mice compared with Apoe/mice. Similarly, aldoste-
rone increased vascular cell adhesionmolecule 1 expression inmouse aortic endothelial cells, an effect
mimickedbycorticosteroneonly in thepresenceofan11-HSD2 inhibitor. Thus, lossof11-HSD2 leads
to striking atherogenesis associated with activation of MR, stimulating proinflammatory processes in
the endothelium of E/b2 mice. (Endocrinology 152: 236–246, 2011)
Atherosclerosis is a chronic inflammatory response toinjury in the vessel wall, yet the initiating events that
precede leukocyte accumulation and fat deposition lead-
ing to plaque development remain poorly defined. Min-
eralocorticoid receptor (MR)antagonists, administered as
diuretics at doses that do not significantly lower blood
pressure, improve survival in heart failure (1), and acute
myocardial infarction (2) in humans. Activation ofMR in
the vasculature is also proinflammatory and proathero-
genic (3), suggesting protective effects of MR antagonism
on the cardiovascular system, independent of blood pres-
sure. However, themechanisms associatedwith these car-
dio-protective effects in humans are yet to be determined.
MR are also high affinity glucocorticoid receptors (4), yet
in mineralocorticoid target tissues, including the distal
nephron, MR are selective for aldosterone, their physio-
logical ligand, despite higher (100-fold) circulating lev-
els of glucocorticoid (5). This selectivity at least in part is
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a consequence of prereceptor metabolism of glucocorti-
coids to intrinsically inert 11-keto-glucocorticoids by
11-hydroxysteroid dehydrogenase type 2 (11-HSD2)
(6). The pathophysiologic importance of 11-HSD2 is
demonstrated in patients with the syndrome of apparent
mineralocorticoid excess causedbymutations inHsd11b2, the
human gene encoding 11-HSD2 (7). Loss of 11-HSD2
results in inappropriate activation of MR by glucocorti-
coids in the distal nephron causing hypokalemia and hy-
pertension (8). Similarly, 11-HSD2/ mice are also
hypertensive, with activation ofMR in the distal nephron
causing increased sodium reabsorption and potassium ex-
cretion (9).
Evidence supports a proatherogenic action of cortisol
within the vessel wall (10). Glucocorticoid pharmacother-
apy in humans is associatedwith increased cardiovascular
events (11).
We and others have demonstrated the existence of the
MR/11-HSD2 system in nonepithelial tissues, including
the vasculature (12). Thus, proatherogenic effects of MR
activation could be mediated directly by increased miner-
alocorticoid hormones or through by-pass or reduced ac-
tivity of vascular 11-HSD2, permitting glucocorticoid
activation of vascular MR. All known inhibitors of 11-
HSD2 can also inhibit 11-HSD1 activity (13) and com-
promise the endothelial barrier by interacting with tight
junctionproteins (14).Therefore,wehave investigated the
underlying mechanism in Apoe//Hsd11b2/ double-
knockout (E/b2) mice, lacking both apolipoprotein E
(ApoE) and 11-HSD2.
Materials and Methods
Generation of ApoE/Hsd11b2 double-knockout
animals
All animal studies were conducted in accordance with the
National Institutes of Health guidelines for the Care and Use of
LaboratoryAnimals under the auspices of theAnimals (Scientific
Procedures)ActUK1986after prior approval by the local ethical
committee. The previously targeted Hsd11b2 allele (9) was
transferred to C57BL/6J by nine generations of consecutive
backcrosses. Two C57Bl/6J females homozygous for deletion of
the Hsd11b2 allele were crossed with an Apoe-knockout
(Apoe/) male on the C57Bl/6J background (Charles River,
L’Arbresle Cedex, France) derived from the original knockout line
(15). Double heterozygousmale offspring (Apoe//Hsd11b2/)
were backcrossed to Apoe/ females; progeny was subsequently
intercrossed to produce double homozygous knockout animals
(Apoe//Hsd11b2/). The colony was maintained by crossing
homozygous Apoe//Hsd11b2/ knockout males (E/b2) to
Apoe//Hsd11b2/ females; double-knockout E/b2 progeny
was selected for experimental protocols. Genotyping was per-
formedbyPCRusing genomicDNAextracted fromear clips.Apoe
primers were located outside the neocassette inserted into exons 3
and 4 (ApoEex3f, AACTTACTCTACACAGGATGCC;Apoe
ex4r, CGTCATAGTGTCCTCCATCAGTGC). These primers
amplify both the wild-type allele (584 bp) and the knockout allele
(1500 bp). PCR conditions were as follows: denaturation at 94 C
for 5 min, then 3 min of elongation at 72 C, followed by 32 cycles
of94Cfor30sec,58Cfor1min, and72Cfor2min.TheHsd11b2
allele (981 bp) was amplified with primers 11b2_679f, AGGCTG
ATG ATA GAT TCA CGA GAC; and 11b2_1660r, CGA ATG
TGT CCA TAA GCA GTG. The knockout allele was amplified
using the genomic primer 11b2_679f (above) and primer
Neof1441, GCGAATGGGCTGACCGCTTCCTCG, comple-
mentary to theNeo gene sequence in the targeting cassette inserted
in the reverse orientation.
Animal treatments
Male Apoe/ and E/b2 mice were maintained on normal
chowdietwithwaterad libitumanda12-h light, 12-hdark cycle.
Systolic blood pressure (SBP) was measured in conscious, re-
strained mice by noninvasive tail cuff plethysmography (16).
This procedure was repeated on a weekly basis during the first
month followed by monthly measurements until termination.
Representative Apoe/ and E/b2 mice were killed by asphyxi-
ation with CO2 at age 3 and 6 months for assessment of athero-
sclerotic lesion formation. To evaluate the effects of drugs,
2-month-old male E/b2 and Apoe/ mice were randomized to
receive normal chow diet containing the MR antagonist
eplerenone (200 mg/kg  d), the epithelial sodium channel
(ENaC) blocker amiloride (1 mg/kg  d; n  9) that acts down-
stream of renal MR to lower blood pressure (17), or vehicle for
3 months.
Tissue preparation for assessment of
atherosclerosis
After euthanasia, the vasculature was perfusion fixed in situ
with 10% neutral-buffered paraformaldehyde via the left ven-
tricle. Arteries removed included the aorta and the following
major branches: brachiocephalic (innominate) artery and its
branches, the right subclavian and right common carotid arter-
ies, the left common carotid and left subclavian arteries, and the
major branches of the abdominal aorta, including the celiac,
superior mesenteric arteries, and the renal arteries.
Semiquantitative gross assessment of
atherosclerosis in the arterial tree
Adventitia were dissected from fixed arteries under a dissect-
ing microscope. Atherosclerotic lesions were visualized through
the translucent arterial wall as yellowish-white opaque deposits.
A semiquantitative scoring system was applied for atheroscle-
rotic deposits at the following sites: 1) lesser curvature of the
aortic arch, 2) origins of principal branches of thoracic aorta
(brachiocephalic, left common carotid, and left subclavian ar-
teries), 3) origin of right and distal right and left common carotid
arteries, 4) distal right and left subclavian arteries, and 5) prin-
cipal branches of abdominal aorta (celiac, superior mesenteric,
and renal arteries). Scoring was based on the following criteria:
0, absent; 1, trace; 2, mild; 3, moderate; and 4, severe.
Arterial trees from all mice of both genotypeswere coded and
read blind by two independent observers. For each site, the ar-
terial tree with the most severe deposit was assigned a score of 4.
The remaining coded arterial trees were then assigned a score
based on that sample.
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Quantification of atherosclerotic lesion size
The brachiocephalic artery was dissected out to provide a
Y-shaped piece of vessel containing the origins of the subclavian
and carotid arteries; this was embedded in paraffin. Serial sec-
tions (3 m) were taken from the proximal 60 m of the bra-
chiocephalic artery once the leaflets of the aortic arch were no
longer visible. Sections were stained with US trichrome (UST);
plaque sizes were quantified by light microscopy (Zeiss Ax-
ioscop; magnification,10; Zeiss, Oberkochen, Germany) with
computerized planimetry (MCID Basic 7.0 image analysis soft-
ware; Imaging Research, Inc., Brock University, St. Catherines,
Ontario,Canada). The area inside the internal elastic laminawas
subtracted from the area inside the external elastic lamina to
provide a measure of media area. Subclavian arteries from ran-
domly selected mice in the drug study were also paraffin embed-
ded and sectioned as above for morphometric studies.
Immunohistochemistry
Plaque collagen content was assessed by Picrosirius red stain-
ing and extracellular lipid content by quantification of the holes
left behind during histological processing of UST-stained sec-
tions (18). Plaque macrophage and smooth muscle cell (SMC)
contentwas assessedusingMac-2 (VHBIO,Gateshead,UK) and
smooth muscle -actin (Sigma, Poole, UK) antibodies, respec-
tively.Vascular cell adhesionmolecule 1 (VCAM-1) (Cambridge
Biosciences, Cambridge, UK) antibody was used to investigate
adhesionmolecule expression (for details, please see Supplemen-
tal data, published on The Endocrine Society’s Journals Online
web site at http://endo.endojournals.org). Staining was imaged
using a light microscope (Zeiss Axioskop) coupled to a Photo-
metrics CoolSnap camera (Tucson, AZ). Photoshop CS3 Ex-
tended software was used to quantify staining, and data are ex-
pressed as stained areas relative to total plaque size (percentage).
A semiquantitative scoring method (carried out blind to geno-
type) was employed to assess VCAM-1 expression, where an
arbitrary score of 0–4 was given to each section based on the
percentage of the circumference of the specific endothelial
staining.
Cell culture
Mouse aortic endothelial cells (MAECs cell line) (19) were
maintained in endothelial basal medium 2 (Lonza, Slough, UK)
supplemented with 10% fetal calf serum and Pen/Strep. Cells
were treated overnight in serum-free medium with one of the
following: 10 ng/ml TNF- (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), 1 nM aldosterone in the presence/absence of 1
M spironolactone, 1 nM corticosterone in the presence/absence
of 1 M glycyrrhetinic acid, and 1 M spironalactone (all from
Sigma). VCAM-1 expression was quantified by counting the
number of positively stained cells per field (at magnification,
40) in four separate fields for each treatment.
FIG. 1. Accelerated atherosclerosis in Apoe/ mice on a standard
low-fat diet. A, Atherosclerotic lesions and outward remodeling were
evident in the brachiocephalic arteries of 3-month-old E/b2 mice but
not in Apoe/ mice (UST stain; magnification, 10). B, At 6 months
of age, lesion development and outward remodeling were significantly
greater in E/b2 than in Apoe/ mice. The example used for Apoe/
shows the largest plaque seen at this age (UST stain; magnification,
10). Lesions in E/b2 were more complex with evidence of buried
fibrous caps (black arrows). Scale bar, 250 m. C, Quantitative analysis
confirmed that lesion sizes were increased, and lumens were reduced
in E/b2 mice compared with Apoe/ mice. Data are means  SEM; *,
P  0.05; **, P  0.01 compared with Apoe/ using Student’s
unpaired t test (n  4–8).
TABLE 1. Increased atherogenesis in E/b2 mice
3 months 6 months
Apoe/ (4) E/b2 (8) Apoe/ (6) E/b2 (8)
Area inside EEL (103 m2) 100  18 243  30a 182  24 352  27b
Medial area (103 m2) 39.6  9.1 100.2  10.4b 53  7.3 110  5.4b
Lesion area (103 m2) 1.4  1.4 48.1  13.9a 8.3  7.1 151.0  15.8b
Lumen area (103 m2) 59.0  10.0 95.0  12.0 127  15.2 90.0  16
Buried caps 0 0 0 1.86  0.24b
Macrophages % plaque area 0 (no plaques) 13.9  5.2 (4) 7.7  2.4 (4) 22.5  2.1 (5)b
Histological analysis of brachiocephalic arteries identified extensive atherosclerotic lesions in 3-month-old E/b2 mice but not in age-matched Apoe/
mice. At 6 months of age, lesion size remained significantly increased in E/b2 compared with Apoe/ mice. The differences in lesion size were
significant whether expressed as mm2 or as a percentage of the lesion area (lesion/area inside the external elastic lamina  100) (Fig. 1). Increased
lesion development in E/b2 mice reduced the percentage luminal area (lumen/lumen  lesion area  100), compared with Apoe/ mice mice at
both 3 and 6 months of age (Fig. 1). Absolute lumen area (mm2) was not reduced in E/b2 mice due to extensive outward remodeling of the vessel
(indicated by increased total area within the external elastic lamina). Buried fibrous caps were evident only in 6-month-old E/b2 mice. These may
be an indication of lesion ‘vulnerability.’ Data are mean  SEM, with group sizes shown in parentheses (n). EEL, External elastic lamina.
a P  0.05.
b P  0.01 compared to age-matched Apoe/ mice (Student’s unpaired t test).
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Plasma lipid and lipoprotein analysis
Terminal blood samples were taken for lipid analysis from
the left ventricle of vehicle- and drug-treated E/b2 and
Apoe/ mice. Total plasma cholesterol was measured by a
colorimetric reaction using the Cholesterol/Cholesteryl Ester
Quantification kit (Merck, Whitehouse Station, NJ).
Statistical analyses
Data were analyzed by the GraphPad
Prism analysis package (GraphPad, San Di-
ego, CA). Data are expressed as means 
SEM. For analysis of unpaired datasets, Stu-
dent’s unpaired t test was used for compar-
ison of two groups, and one-way ANOVA
with Tukey’s post hoc test was used for
more than two groups. Repeated measures
ANOVA was used for comparison of
matched datasets. Two-way ANOVA fol-
lowedbyBonferronipost hoc testswas used
for analyzing the effects of drug treatments
between groups. Scored data were analyzed
by a nonparametric Kruskal-Wallis one-
way ANOVA followed by Dunn’s post hoc
test. A P value of less than 0.05 was con-
sidered to be statistically significant.
Results
E/b2 mice show accelerated
atherosclerosis
E/b2 mice were born in the ex-
pectedMendelian numbers toApoe/
Hsd11b2/ females mated with E/b2
males and showed no difference in
weight gain to Apoe/Hsd11b2/ lit-
termates or age-matched Apoe/mice.
At 3 months of age, Apoe/ mice
raised on a standard chow diet dis-
played few, if any, signs of atheroscle-
rosis in the brachiocephalic artery (Fig.
1A). In contrast, by 3 months of age on
the same diet, E/b2 mice lacking both
11-HSD2 and ApoE displayed ather-
oma (lipid core and proliferating
SMCs) with occasional thin fibrous
caps, affecting the aortic arch and its
major branches, including the brachio-
cephalic trunk (Fig. 1A), a site partic-
ularly susceptible to plaque develop-
ment in these animals when fed an
atherogenic “Western” diet (20). At 3
months, somesevere lesionswerealready
present in E/b2 mice, with extended
necrotic areas, cholesterol clefts, neo-
intimal expansion, and elastic lamina
remodeling.
By 6 months of age, E/b2 mice dis-
played complex severe atherosclerotic
FIG. 2. Accelerated atherosclerosis in E/b2 mice is associated with macrophage infiltration
and altered plaque composition. A, At 3 months of age, Apoe/ mice are lesion free,
whereas E/b2 mice show macrophage-infiltrated plaques (staining with anti-Mac-2 antibodies)
with a high lipid and low collagen content. By 6 months, E/b2 mice have large macrophage-
rich plaques with a high density of lipids and sparse collagen staining. In comparison, 6-
month-old Apoe/ mice have plaques that are rich in collagen and low in lipid and
macrophage content. E/b2 and Apoe/ mice at both ages show similar levels of -SMA
staining, indicative of SMC within their plaques. Representative images (of six mice per group,
except in case of 6-month-old Apoe/, where uncommon larger plaques were selected to
investigate composition) captured at magnification, 10. Arrows indicate regions of interest
corresponding to names of each column. Scale bar, 250 m. B–E, The area of staining for
each plaque component was quantified using Photoshop CS3 Extended software and
expressed as a percentage of total plaque area. Macrophage (B) and lipid (C) contents were
both increased in brachiocephalic plaques from 3- and 6-month-old E/b2 mice compared with
those from Apoe/ mice at 6 months of age. There was no difference in the -SMA (D)
content of plaques between Apoe/ and E/b2 mice at either 3 or 6 months of age. Collagen
(E) content was reduced in brachiocephalic plaques from 3- and 6-month E/b2 mice
compared with those from Apoe/ mice at 6 months of age. Data are mean  SEM, n  5–
7/group. Analyzed by two-way ANOVA; *, P  0.05; **, P  0.005.
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lesions withmultiple fibrous caps (Fig. 1B). Importantly,
these included buried caps, which have been suggested
as being indicative of earlier plaque instability (Fig. 1B
and Table 1) (21). However, in 6-month-old Apoe/
mice raised on the same chow diet, atherosclerosis re-
mained sporadic (only one of the six animals in this
group had a notable plaque; example shown in Fig. 1B)
in the brachiocephalic artery (Fig. 1B). This remarkable
increase in atherosclerosis with 11-HSD2 deficiency
was despite similar plasma cholesterol levels between
E/b2 (306  54 mg/dl) and Apoe/ (288  46 mg/dl)
mice.
Quantitative analysis of the areas inside the external
elastic lamina, lesion areas, and lumen areas of the bra-
chiocephalic artery revealed significantly larger athero-
sclerotic lesions in E/b2 mice at 3 and 6 months of age
compared with age-matched Apoe/ mice (Fig. 1C and
Table 1). There was also a significant reduction of lumen
size relative to the size of the vessel (Fig. 1C and Table 1),
although the absolute lumen size was maintained (vessel
diameter was also increased), suggestive of expansive re-
modeling in E/b2 mice.
Plaque composition is altered in E/b2 mice
Immunohistochemical staining revealed that athero-
sclerotic plaques in brachiocephalic arteries of
6-month-old E/b2 mice contained dense accumulations
of macrophages and foam cells (Fig. 2A), most notably
at the “shoulder” of lesions and near buried fibrous
caps. Macrophage infiltration (Fig. 2B), and lipid con-
tent of plaques (Fig. 2C) were both significantly greater
in E/b2 than in Apoe/ mice. Furthermore, plaques in
3-month-old Eb/2 mice contained significantly more
macrophages (Fig. 2B) and lipid (Fig. 2C) than those in
plaque size-matched Apoe/ counterparts (examples
of rare plaques from 6-month-old Apoe/ mice se-
lected to show composition). SMC content of plaques,
assessed by -smooth muscle actin (SMA) immunore-
activity, did not differ between E/b2 and Apoe/ mice
(Fig. 2D). Picrosirius red staining of collagen was sig-
nificantly lower in plaques from 3- and 6-month-old
E/b2 mice compared with plaques from 6-month-old
Apoe/ mice (Fig. 2E). Thus, 11-HSD2 deficiency
promotes the formation of collagen-poor, lipid-, and
macrophage-rich plaques, suggestive of a “vulnerable”
plaque phenotype.
Accelerated atherosclerosis in E/b2 mice is
associated with increased expression of VCAM-1
VCAM-1 immunoreactivity was significantly higher in
unaffected areas of brachiocephalic artery endothelium in
both 3- and 6-month-old E/b2 mice compared with age-
matched Apoe/ controls (Fig. 3) both in the endothe-
lium covering the plaque and in plaque-free regions of the
vessel wall. Importantly, comparison of similar-sized ves-
sels from 3-month-old E/b2 mice and 6-month-old
Apoe/ mice showed significantly higher VCAM-1 ex-
pression in E/b2 mice, despite their younger age (Fig. 3, A
and B).
Atheroprotective effects of eplerenone and
amiloride do not correlate with their ability
to lower blood pressure
As anticipated from the previously reported phenotype
of Hsd11b2/ mice (9), E/b2 animals were moderately
hypertensive compared with Apoe/ mice, most likely
due to overactivation of MR in the kidney (SBP 141.8 
2.5 mm Hg in E/b2 mice vs. 112.6  1.7 mm Hg in
Apoe/mice; P 0.001). Thus, the exacerbated athero-
FIG. 3. Endothelial cell expression of VCAM-1 is up-regulated in E/b2
mice. A, Apoe/ mice at 3 months show sparse endothelial staining
for VCAM-1 (top left panel), whereas age-matched E/b2 mice have
more abundant and intense VCAM-1 immunoreactivity (top middle
panel). At 6 months, Apoe/ mice (bottom left panel) show increased
VCAM-1 staining compared with 3-month-old Apoe/ mice, but it is
still lower than in E/b2 mice (bottom right panel). Arrows indicate
specific staining for VCAM-1 in endothelium (highlighted in embedded
boxes). Adventitia is stained nonspecifically as a result of entrapment
of streptavidin-horseradish peroxidase complex (see negative control).
Representative images (of four to six mice per group) captured at
magnification, 10. Scale bar, 250 m. B, VCAM-1 staining is
significantly greater in endothelium of 3- and 6-month-old E/b2 mice
compared with age-matched Apoe/ mice. At 3 months, VCAM-1
expression is higher in E/b2 vessels compared with Apoe/ mice at 6
months with the same size of plaques. Data are means  SEM, n  4–
6/group. Analyzed by Kruskal-Wallis nonparametric test; ***, P 
0.0001. Scoring: 0, absent; 1, 25% circumference stained; 2, 25–
50% circumference stained; 3, 50–75% circumference stained; 4,
75% circumference stained.
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sclerosis in E/b2 mice could be attributable to hyperten-
sion as a result of renalMR activation by glucocorticoids,
or to a direct effect of 11-HSD2-deficiency within the
vascularwall or a combinationof these factors.Toaddress
MR involvement and to determine the dependency of the
phenotype on hypertension, 2-month-old mice were fed
chowdiet containing vehicle or one of two pharmacologic
inhibitors for 3 months: amiloride, an
ENaC blocker that acts downstream of
renal MR to lower blood pressure, and
eplerenone, a highly selective MR an-
tagonist. The dose chosen for the latter
(200mg/kg  d in chow)was previously
shown to reduce atheroma formation
in Apoe/mice administered aldoste-
rone (22). We found no effect of any
drug treatment on blood pressure
of Apoe/ mice (data not shown).
Eplerenone had no significant effect on
SBP inE/b2mice,whereas amiloride re-
duced it by approximately 11 mm Hg,
almost halving the blood pressure dif-
ference between E/b2 and Apoe/
mice (Fig. 4A). However, despite being
less effective as a hypotensive drug,
eplerenone was more effective than
amiloride in reducing overall plaque
score as estimated by blinded, semi-
quantitative scoring assessed across
five sites (Fig. 4, B and C). Quantita-
tive histological analysis showed that
eplerenone also dramatically reduced
plaque size and the expansive remodel-
ing in subclavian arteries, which are
particularly prone to large occlusive
plaques in E/b2 mice (Fig. 4, D and E).
Both eplerenone and amiloride reduced
lesion size in brachiocephalic arteries
(Fig. 4, F and G, and Table 2). The pat-
tern of expansive remodeling evident in
untreated E/b2 mice was also reduced
after treatment with both eplerenone
and amiloride (Table 2). Thus, the
stronger atheroprotective effect of
eplerenone in comparison with amilo-
ride, with the latter producing a larger
reduction in blood pressure, indicates
that the predominant mechanism lead-
ing to accelerated atherosclerosis in
E/b2 mice is unlikely to be attributable
simply to hypertension after renal MR
activation.
MR activation contributes to the altered plaque
composition in E/b2 mice
To investigate whetherMR antagonism altered plaque
composition in addition to reducing lesion size in E/b2
mice,macrophage infiltration,-SMA, collagen, and lipid
contentweremeasured in brachiocephalic plaques of E/b2
FIG. 4. Eplerenone reduces lesion size in E/b2 mice, independently of blood pressure. A, SBP
in E/b2 and Apoe/ mice was reduced in E/b2 mice by treatment with amiloride but not by
eplerenone. *, P  0.05 vs. age 3 and 4 months, repeated measures ANOVA. B,
Representative images of the aortic arch and its branches in 5-month-old E/b2 mice after
vehicle (left panel), amiloride (center panel), or eplerenone (right panel) treatment. aa, Aortic
arch; ca, carotid artery; sca, subclavian artery; bc, brachiocephalic artery. C, Semiquantitative
analysis of lesion development using global plaque score (for details, please see Materials and
Methods). **, P  0.01 vs. untreated E/b2 Kruskal-Wallis test, n  6–11. D, Representative
images of UST-stained plaques in subclavian arteries of 5-month-old E/b2 mice after vehicle
(left), amiloride (center), and eplerenone (right) treatment. Images captured at magnification,
10. Scale bar, 250 m. E, Measurement of lesion size; *, P  0.05 vs. untreated E/b2 mice,
one-way ANOVA, n  4–5). F, Representative images of UST-stained plaques in
brachiocephalic arteries of E/b2 mice after vehicle (left), amiloride (center), and eplerenone
(right) treatment. Images captured at magnification, 10. Scale bar, 250 m. G,
Measurement of lesion size; *, P  0.05 vs. untreated E/b2; two-way ANOVA, n  7–10.
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mice after 3 months of treatment with eplerenone or ve-
hicle. Macrophage content was significantly reduced by
eplerenone treatment (Fig. 5, A and B). Despite the in-
crease in lipid content of plaques in E/b2 mice compared
withApoe/mice,MRblockadewith eplerenone had no
effect on plaque lipid content in E/b2 mice (Fig. 5, A and
C). Surprisingly, although there was no difference in
plaque -SMA content between E/b2 and Apoe/ mice,
SMC content was significantly increased byMRblockade
in E/b2 mice (Fig. 5, A and D). Eplerenone treatment also
significantly increased plaque collagen content compared
with vehicle-treatedE/2bmice (Fig. 5,A andE). Therewas
a trend toward a reduction in the incidence of buried fi-
brous caps in the brachiocephalic artery of eplerenone-
treated E/b2 mice (1.10  0.31 buried caps for vehicle-
treated mice vs. 0.56  0.18 for eplerenone-treated E/b2
mice).
Glucocorticoids in the presence of 11-HSD2
inhibitor cause MR-mediated up-regulation of
VCAM-1 expression in vitro
MAECs were used to test whether mineralocorticoids
or glucocorticoids acting throughMRcanaffectVCAM-1
expression and whether 11-HSD2 inhibition may be im-
portant in regulation ofMR specificity. Similar to TNF-,
which potently increases VCAM-1 expression in endothe-
lial cells (23), aldosteronemarkedly increased the number
ofMAECexpressingVCAM-1 (7-fold) (Fig. 6), an effect
blocked by pretreatment with the MR antagonist, spi-
ronolactone, suggesting an MR-mediated mechanism.
Corticosterone alone had no effect on VCAM-1 expres-
sion. However, inhibition of 11-HSD2 by pretreatment
with glycyrrhetinic acid [awidely used 11-HSD inhibitor
(24), which had no effect on VCAM-1 expression on its
own] allowed corticosterone to induce a more than 9-fold
increase in the number of VCAM-1-stained cells (Fig. 6).
Using RT-PCR, we have confirmed that 11-HSD1 is not
expressed in MAEC (data not shown). Thus, in this cell
line, as in kidney, 11-HSD2 protects MR from acti-
vation by glucocorticoids. Consistent withMR involve-
ment, VCAM-1 up-regulation by corticosterone in the
presence of glycyrrhetinic acid was reversed by block-
ade of MR with spironolactone (Fig. 6B).
Discussion
Early development of severe occlusive atheromatous
plaques in E/b2 mice provides a new experimental model
of atherosclerosis, mechanistically underpinned by glu-
cocorticoid-mediated activation of MR. In contrast to
most existingmodels, high fat/Western diet is not required
for the development of atherosclerosis in Eb/2 mice. In-
deed, when fed a chow diet, Apoe/ mice exhibit mod-
erate hyperlipidemia and only develop mature atheroma-
tous plaques at 8–10months of age (25). FeedingApoe/
mice a Western diet (containing cholesterol) increases
plasma cholesterol, induces systemic inflammation, and
accelerates atherogenesis so that lesions appear within 5
wk (20). It therefore appears that progressive atheroscle-
rosis in Apoe/ mice is strictly dependent on systemic
inflammation and elevated plasma cholesterol associated
with the Western diet.
Atherogenesis in E/b2 mice was associated with early
and increased macrophage infiltration of brachiocephalic
lesions, even when matched with similar-sized lesions in
older Apoe/mice. An increase in the number of buried
caps inplaquesofolderE/b2animals could reflectmultiple
events of plaque rupture and repair in E/b2 mice, typical
of vulnerable plaques. Thus, for investigation of the pro-
cesses leading toavulnerableplaquephenotype,E/b2mice
maybeabetter experimental platformthanApoe/mice.
The ability of eplerenone administration to reduce
plaque size and alter plaque composition implicatesMR
TABLE 2. Histological analysis of the effect of treatment with amiloride or eplerenone on atherosclerotic lesion
development in the brachiocephalic artery of E/b2 mice and Apoe/ mice
E/b2
Apoe/ vehicle (10)Vehicle (10) Amiloride (7) Eplerenone (9)
Area inside EEL (103 m2) 400  25.0c 321  27.2a 304  33.8b 177  9
Medial area (103 m2) 119  8.6c 96.8  5.0 89.6  8.7b 51.4  3.7
Lesion area (103 m2) 137  15.4c 87.2  17.2a 83.9  19.1b 5.8  3.9
Lumen area (103 m2) 144.4  9.7 137.6  19.8 130.5  10.4 119.7  6.7
Buried caps 1.1  0.31 0.86  0.26 0.56  0.18 0
Vehicle-treated E/b2 mice demonstrated significant remodeling and atherosclerotic lesion formation compared with vehicle-treated Apoe/ mice.
Treatment of E/b2 mice with either amiloride or eplerenone significantly reduced the degree of vascular remodeling and atherosclerotic lesion
formation in this vascular bed. Data are mean  SEM, with group sizes shown in parentheses (n). EEL, External elastic lamina.
a P  0.05.
b P  0.01 when compared with vehicle-treated E/b2 mice, two-way ANOVA.
c P  0.001, genotype comparison by Student’s unpaired t test.
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activation as mechanistically important in accelerating
atherosclerosis in E/b2mice. This is consistent with pre-
vious data showing that aldosterone is proatherogenic
in animal models (23, 26), although this has not been
replicated in all studies (27). Moreover, eplerenone has
beneficial effects on experimental atherosclerosis in non-
human primates (28), again implicatingMR activation in
pathogenesis of atherosclerosis. This raises the possibility
that the proatherogenic effects of MR activation are
through cortisol (a glucocorticoid) rather than the miner-
alocorticoid, aldosterone.
Crucially, the effect of eplerenone on atherosclerosis in
E/b2 mice was independent of MR effects on blood pres-
sure (which was unaltered in E/b2 mice
by this modest dose of eplerenone). In
the absence of 11-HSD2, MR are not
protected from activation by glu-
cocorticoids, and their activation in
the distal nephron increases activity
of ENaCs and Na/K ATPase, leading
to hypertension (17). The extent of
hypertension in E/b2 mice was compa-
rable with that previously reported in
single-knockoutHsd11b2/mice (9).
Bypassing MR activation with the
ENaCblocker amiloride reducedblood
pressure in E/b2 mice but was less ef-
fective in diminishing atherosclerosis
than eplerenone. Hypertension in
Hsd11b2/ mice is initiated by MR
activation and volume expansion, but
already after 2.5months of age, activity
of ENaC was returned to the basal
level, and high blood pressure was
maintained by activation of  1-ad-
renergic receptors (26). Hence,
eplerenone cannot effectively normal-
ize blood pressure at these later stages,
whereas amiloride still can. Another
possible contributor to hypertension in
Hsd11b2 deficiency is the vasoconstric-
tive effectmediated by glucocorticoid re-
ceptors (29, 30), which will not be af-
fectedby theMRantagonist, eplerenone.
Thus, although hypertension may
play a part in the accelerated athero-
genesis in E/b2 mice, there is clearly a
component of atherogenesis that is not
merely due to the hypertension of “ap-
parent mineralocorticoid excess” pro-
duced byMR overactivation in the dis-
tal nephron. This concurs with two
previous studies in which blood pres-
sure played little or no role in atherogenesis: in mice de-
ficient for bothApoEandendothelial nitric oxide synthase
(31) and Apoe/ mice with renovascular hypertension
(one kidney/one clip and two kidneys/two clips models)
(32). In contrast, bloodpressureper seplayedonly aminor
role in atheroma progression in Apoe/mice with reno-
vascular hypertension compared with the large effect of
angiotensin II (33).
Our data implicate activation of nonrenal MR in the
pathogenesis of accelerated atherogenesis in E/b2 mice
with the vascular wall being themost likely candidate site.
In humans, 11-HSD2 immunoreactivity has been re-
FIG. 5. MR blockade reduces macrophage infiltration and alters plaque composition in E/b2
mice. A, Representative images of atherosclerotic plaques from vehicle- treated (Veh) (top
panels) and eplerenone-treated (Epl) (200 mg/kg  d; lower panels) E/b2 mice, stained with
UST (lipid holes), Mac-2 antibody (Mac-2), -SMA antibody (SMA), or Picrosirius red
(collagen), captured at magnification, 10. Arrows indicate regions of interest corresponding
to names of each column. Scale bar, 250 m. Compared with vehicle-treated mice, plaques
in eplerenone-treated E/b2 mice demonstrated reduced Mac-2 staining (B) with increased
staining for -SMA (D) and collagen (E). There was no apparent difference in lipid content,
compared with plaques in vehicle treated E/b2 mice (C). The area of staining was quantified
using Photoshop CS3 Extended software and expressed as a percentage of total plaque area.
Data are mean  SEM, n  4–5. Analyzed by Student’s unpaired t test; *, P  0.05.
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ported in arterioles and veins (34) with immunoreactivity
and enzyme activity concentrated in endothelial cells (35).
Both 11-HSD2mRNA and enzyme activity are found in
rodent vessels,most likely including the endothelium (36).
Consistent with colocalization of MR and 11-HSD2 in
endothelial cells, MAEC in vitro also have functionalMR
and 11-HSD2. In vitro, activation ofMRby aldosterone
increases leukocyte adhesionmolecules in primary human
endothelial cells from umbilical cord (37). It was shown
recently that aldosterone stimulates transcription of the
proatherogenic leukocyte-endothelial cell adhesion pro-
teins in human coronary artery and aortic endothelial
cells. In the same study, inhibition of 11-HSD2 enhanced
cortisol-induced transcription of a reporter transgene me-
diatedbyMRinaortic endothelial cells (38).Weshowthat
VCAM-1 expressionwas increased in vivo in E/b2mice in
affected and unaffected regions of the brachiocephalic ar-
tery. A direct effect of MR in this increase (rather than an
effect of shear stress) is supported by the MR-dependent
potent increase in VCAM-1 expression in MAECs treated
with aldosterone orwith corticosterone in the presence of an
11-HSD2 inhibitor. VCAM-1 increases monocyte/macro-
phage adhesion to endothelial cells (39) and is mechanisti-
cally linked to inflammatory processes (40) and atheroma
development in Apoe/ (41) and Ldlr/ mice (42). In-
creased expression of VCAM-1 in E/b2 mice may be re-
sponsible for the increased macrophage infiltration lead-
ing to accelerated atherogenesis and may also stimulate
expansive vessel remodeling (43).
Overall, these findings indicate that loss of function of
11-HSD2 leads to striking atherogenesis in E/b2 mice
mediated by activation of nonrenal MR. Endothelial ex-
pression of VCAM-1 and massive infiltration of the ath-
erosclerotic plaques by macrophages at moderately ele-
vated levels of plasma cholesterol are the characteristic
features of this new mouse model of atherosclerosis.
We have shown for the first time that 11-HSD2 is
atheroprotective. In its absence, activation of MR
mainly by glucocorticoids enhances inflammatory pro-
cesses in the atherosclerotic plaque. This effect ofMR is
not solely attributable to changes in blood pressure.
Whether it is associated with the altered activation
mechanisms of MR in the endothelium remains to be
investigated in the future experiments with tissue spe-
cific knockout of MR.
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